Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793660 | 0.84 | SMN1; SMN2 (0.44) | NOS1TSHRSMN1; SMN2LMNAGAA | |
| SCHEMBL507495 | 0.84 | SMN1; SMN2 (0.44) | NOS1TSHRSMN1; SMN2LMNAGAA | |
| SCHEMBL4946269 | 0.81 | KCNH2 (0.39) | TAAR1CYP1A2CYP2D6CYP2C19MAOA | |
| SCHEMBL29793575 | 0.78 | NOS1 (0.41) | CYP2D6NOS1TSHRSMN1; SMN2 | |
| SCHEMBL29866080 | 0.78 | TSHR (0.39) | TSHRSMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL6158666 | 0.78 | TSHR (0.39) | TSHRSMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL856097 | 0.78 | OPRM1 (0.40) | TSHRSMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL27899553 | 0.76 | TSHR (0.38) | CYP1A2TSHRSMN1; SMN2LMNAGAA | |
| SCHEMBL4945517 | 0.75 | TDP1 (0.49) | CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL27652959 | 0.75 | TSHR (0.40) | TSHRSMN1; SMN2LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100439366-C | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| CN-1894245-A | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | TAAR1 983/4885CYP1A2 67/4885CYP2D6 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.